Advance of sporadic Alzheimer’s disease animal models
Advance of sporadic Alzheimer’s disease animal models
复制标题
散发性阿尔茨海默病动物模型的研究进展
DOI：
10.1002/med.21624
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Rongbiao Pi
中科院分区：
文献类型：
--
作者：
Lili Zhang;Chen Chen;Marvin SH Mak;Junfeng Lu;Zeqing Wu;Qiuhe Chen;Yifan Han;Yuefeng Li;Rongbiao Pi
阿尔茨海默病（Alzheimer's disease，AD）是一种进行性神经退行性疾病，是痴呆症中最常见的形式。在过去的几十年中，许多有前途的候选药物在临床前研究中显示出显着的抗AD作用，但在临床试验中失败。其中一个主要原因可能是用于评价抗AD药物的合适动物模型的局限性。超过95%的AD病例是散发性AD（sAD）。然而，抗AD候选药物主要在家族性AD（fAD）动物模型中进行测试。sAD和fAD之间的差异可能导致抗AD药物开发期间的高失败率。因此，抗AD药物的开发迫切需要一种理想的sAD动物模型。本文就sAD动物模型的研究方法、病理特点及可能的发病机制进行综述。本文还讨论了这些sAD动物模型的局限性和该领域的未来发展趋势。
Alzheimer’s disease (AD), the most common form of dementia, is a progressive neurodegenerative disease. In the past decades, numbers of promising drug candidates showed significant anti‐AD effects in preclinical studies but failed in clinical trials. One of the major reasons might be the limitation of appropriate animal models for evaluating anti-AD drugs. More than 95% of AD cases are sporadic AD (sAD). However, the anti‐AD drug candidates were mainly tested in the familial AD (fAD) animal models. The diversity between the sAD and fAD might lead to a high failure rate during the development of anti‐AD drugs. Therefore, an ideal sAD animal model is urgently needed for the development of anti‐AD drugs. Here, we summarized the available sAD animal models, including their methodology, pathologic features, and potential underlying mechanisms. The limitations of these sAD animal models and future trends in the field were also discussed..